T

Turnstone Biologics Corp
NASDAQ:TSBX

Watchlist Manager
Turnstone Biologics Corp
NASDAQ:TSBX
Watchlist
Price: 0.355 USD Market Closed
Market Cap: 8.2m USD

Turnstone Biologics Corp
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Turnstone Biologics Corp
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
T
Turnstone Biologics Corp
NASDAQ:TSBX
Operating Income
-$72.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Turnstone Biologics Corp
Glance View

Market Cap
8.2m USD
Industry
Biotechnology

Turnstone Biologics Corp is a US-based company operating in Biotechnology industry. The company is headquartered in La Jolla, California and currently employs 108 full-time employees. The company went IPO on 2023-07-21. Turnstone Biologics Corp. is a clinical-stage biotechnology company focused on developing new medicines to treat and cure patients with solid tumors. The firm is focused on developing tumor infiltrating lymphocytes (TIL) therapies designed to drive clinical benefit and curative outcomes across multiple solid tumors. Its selected TIL approach focuses on selecting and expanding potent tumor-reactive T cells to overcome the limitations of bulk TILs. Its pipeline includes TIDAL-01 and TIDAL-02. Its lead selected TIL product candidate, TIDAL-01, utilizes an unbiased identification and functional screening process to isolate and selectively expand the breadth of tumor-reactive TILs from the patient’s tumor. Its next selected TIL program, TIDAL-02, is being designed to encompass a streamlined manufacturing process for tumor-reactive T cells and additional modifications to enhance TIL quality and function.

TSBX Intrinsic Value
1.25 USD
Undervaluation 72%
Intrinsic Value
Price
T

See Also

What is Turnstone Biologics Corp's Operating Income?
Operating Income
-72.5m USD

Based on the financial report for Dec 31, 2024, Turnstone Biologics Corp's Operating Income amounts to -72.5m USD.

What is Turnstone Biologics Corp's Operating Income growth rate?
Operating Income CAGR 1Y
-23%

Over the last year, the Operating Income growth was -23%.

Back to Top